🇺🇸 FDA
Patent

US 11466015

Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators

granted A61PA61P25/00

Quick answer

US patent 11466015 (Crystalline forms of 8-(2-fluorobenzyl)-6-(3-(trifluoromethyl)-1H-1,2,4-triazol-5-yl)imidazo[1,2-a]pyrazine as sGC stimulators) held by Cyclerion Therapeutics, Inc. expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cyclerion Therapeutics, Inc.
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61P, A61P25/00